This finding is congruent with an earlier study by Middeke and coworkers in a high‐risk AML cohort indicating favorable posttransplant 2‐year EFS with isolated del(5q) lacking del(17p),16 whereas a more recent EBMT study showed adverse impact of 5q in the context of an abnormal 17(p) or monosomal karyotype,24 although neither study evaluated TP53 mutations. The gene discussed is TP53; the disease is acute myeloid leukemia.